WO2010104314A2 - 비결정형의 (+)-란소프라졸 제조방법 및 이에 사용되는 (+)-란소프라졸 알코올레이트 - Google Patents

비결정형의 (+)-란소프라졸 제조방법 및 이에 사용되는 (+)-란소프라졸 알코올레이트 Download PDF

Info

Publication number
WO2010104314A2
WO2010104314A2 PCT/KR2010/001461 KR2010001461W WO2010104314A2 WO 2010104314 A2 WO2010104314 A2 WO 2010104314A2 KR 2010001461 W KR2010001461 W KR 2010001461W WO 2010104314 A2 WO2010104314 A2 WO 2010104314A2
Authority
WO
WIPO (PCT)
Prior art keywords
lansoprazole
crystalline
alcoholate
same
preparing non
Prior art date
Application number
PCT/KR2010/001461
Other languages
English (en)
French (fr)
Other versions
WO2010104314A3 (ko
Inventor
장선영
김태원
김성범
김병구
전지영
조승환
고명실
서귀현
이관순
Original Assignee
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미약품 주식회사 filed Critical 한미약품 주식회사
Publication of WO2010104314A2 publication Critical patent/WO2010104314A2/ko
Publication of WO2010104314A3 publication Critical patent/WO2010104314A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

(+)-란소프라졸이 용해된 C1-C3의 알코올 용액으로부터 (+)-란소프라졸 알코올레이트를 결정화하여 수득한 뒤 실온 내지 50℃에서 건조하는 것을 포함하는 비결정형의 (+)-란소프라졸을 제조하는 방법에 의하여, 위산 관련 질환의 치료 및 예방을 위한 의약 제제로서 유용한 비결정형의 (+)-란소프라졸을 화학적, 광학적 및 결정학적으로 순수하고 재현성있게 제조할 수 있다.
PCT/KR2010/001461 2009-03-09 2010-03-09 비결정형의 (+)-란소프라졸 제조방법 및 이에 사용되는 (+)-란소프라졸 알코올레이트 WO2010104314A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090019877A KR20100101405A (ko) 2009-03-09 2009-03-09 비결정형의 (+)-란소프라졸 제조방법 및 이에 사용되는 (+)-란소프라졸 알코올레이트
KR10-2009-0019877 2009-03-09

Publications (2)

Publication Number Publication Date
WO2010104314A2 true WO2010104314A2 (ko) 2010-09-16
WO2010104314A3 WO2010104314A3 (ko) 2010-12-09

Family

ID=42728934

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/001461 WO2010104314A2 (ko) 2009-03-09 2010-03-09 비결정형의 (+)-란소프라졸 제조방법 및 이에 사용되는 (+)-란소프라졸 알코올레이트

Country Status (2)

Country Link
KR (1) KR20100101405A (ko)
WO (1) WO2010104314A2 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004387A3 (en) * 2009-06-18 2011-06-23 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578732A (en) * 1987-08-04 1996-11-26 Takeda Chemical Industries, Ltd. Production of 2-(2-pyridylmethylsulfinyl) benzimidazole compounds by selective oxidation in the presence of a vanadium catalyst
KR20040093187A (ko) * 2002-03-27 2004-11-04 테바 파마슈티컬 인더스트리즈 리미티드 란소프라졸 다형 및 그것의 제조 방법
EP1552833A1 (en) * 2002-10-16 2005-07-13 Takeda Chemical Industries, Ltd. Stable solid preparations
WO2008077866A1 (en) * 2006-12-22 2008-07-03 Recordati Industria Chimica E Farmaceutica Spa Process for manufacturing microcrystalline lansoprazole form i

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578732A (en) * 1987-08-04 1996-11-26 Takeda Chemical Industries, Ltd. Production of 2-(2-pyridylmethylsulfinyl) benzimidazole compounds by selective oxidation in the presence of a vanadium catalyst
KR20040093187A (ko) * 2002-03-27 2004-11-04 테바 파마슈티컬 인더스트리즈 리미티드 란소프라졸 다형 및 그것의 제조 방법
EP1552833A1 (en) * 2002-10-16 2005-07-13 Takeda Chemical Industries, Ltd. Stable solid preparations
WO2008077866A1 (en) * 2006-12-22 2008-07-03 Recordati Industria Chimica E Farmaceutica Spa Process for manufacturing microcrystalline lansoprazole form i

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004387A3 (en) * 2009-06-18 2011-06-23 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms

Also Published As

Publication number Publication date
KR20100101405A (ko) 2010-09-17
WO2010104314A3 (ko) 2010-12-09

Similar Documents

Publication Publication Date Title
BRPI0821039B8 (pt) formas sólidas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico, processo de preparação das mesmas, composições farmacêuticas compreendendo as mesmas e usos
AU2016219654A1 (en) Crystallization method and bioavailability
AR062148A1 (es) Proceso quimico para la preparacion de intermediarios
NO20074988L (no) Nye polymorfe former av rifaximin, prosesser for deres fremstilling og anvendelse derav i medisin
WO2008057930A3 (en) Methods of treating neuropathic pain with retinoic acid receptor agonists
PE20121742A1 (es) PROCEDIMIENTO PARA LA PREPARACION DE {4,6-DIAMINO-2-[1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL]PIRIMIDIN-5-IL}METILCARBAMATO DE METILO Y SU PURIFICACION PARA SU USO COMO PRINCIPIO ACTIVO FARMACEUTICO
WO2012090043A8 (en) Novel solid state forms of azilsartan medoxomil and preparation thereof
WO2009100936A3 (de) Neue aromatische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
MA33063B1 (fr) Complexe d'hydrohalogenure d'agomelatine et procede de preparation de celui-ci
NZ602450A (en) Agomelatine hydrochloride hydrate and preparation thereof
WO2008058236A3 (en) Methods for preparing cinacalcet hydrochloride
CL2012000560A1 (es) Procedimiento de preparacion del compuesto intermediario acido 3-oxo-tetrahidrotiofeno-2-carboxilico, utiles en la preparacion de dihidrotienopirimidinas (divisional de la solicitud 3095-08).
WO2014140861A3 (en) Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
EP2669382A4 (en) Cellulosic biomass treatment method, method of producing sugar, alcohol or organic acid from cellulosic biomass
MY171207A (en) Novel process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
GB201319327D0 (en) High purity of caspofungin or salts thereof, and preparation method thereof, and use thereof
IN2011KN05169A (ko)
AR081514A1 (es) El compuesto 4-[etil(dimetil)amonio]butanoato, el metodo para la preparacion del mismo y el uso en el tratamiento de la enfermedad cardiovascular
WO2008152334A3 (fr) Nouveaux dérivés d'acide 3-phenyl acrylique activateurs des récepteurs de type ppar, leur méthode de préparation et leur utilisation dans des compositions cosmétiques ou pharmaceutiques
WO2010104314A2 (ko) 비결정형의 (+)-란소프라졸 제조방법 및 이에 사용되는 (+)-란소프라졸 알코올레이트
WO2009091967A3 (en) Fenofibric acid polymorphs; methods of making; and methods of use thereof
WO2013062294A3 (ko) 미티글리나이드 칼슘염의 개선된 제조방법
WO2012150607A3 (en) Oral liquid composition comprising divalproex sodium and process for preparing thereof
CN107915715A (zh) 一种瑞舒伐他汀钙侧链关键中间体的合成方法
MX2010007923A (es) Forma cristalina de abacavir que esta esencialmente libre de disolvente.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10751005

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10751005

Country of ref document: EP

Kind code of ref document: A2